Beacon BreakingNews – FDA Examining Exjade Safety In MDS Patients
The U.S. Food and Drug Administration announced on its Web site today that it is investigating the safety of the drug Exjade (deferasirox) when prescribed to patients with myelodysplastic syndromes (MDS). The investigation was initiated after an FDA data analysis found that MDS patients taking Exjade appear to have a higher risk of serious, often fatal, side effects.
Exjade is prescribed to MDS patients receiving blood transfusions to reduce the excess levels of iron that often occur as a result of transfusions.
The Beacon will cover this news in more detail in a later news article. For additional information in the interim, please see the related announcement on the FDA Web site.
Update: Please see the MDS Beacon’s full coverage of this news.
Related Articles:
- FDA Analyzing Safety Of Exjade In MDS Patients
- Exjade Not Recommended For High-Risk Myelodysplastic Syndromes Patients
- Exjade May Be More Effective Than Ferriprox In Certain Lower-Risk MDS Patients (EHA 2011)
- Treatment For Excess Iron May Improve Blood Cell Counts In Some Transfusion-Dependent MDS Patients
- FDA Approves Ferriprox … But Not For Myelodysplastic Syndromes Patients
Leave a comment